About the Product

Description


Flunafeb 10 Tablet is a selective calcium channel blocker designed to manage and prevent migraines and vertigo. Flunarizine, the active ingredient, works by reducing the excessive calcium influx in brain cells, which is a key factor in triggering migraines and vascular headaches. It also enhances blood flow to the brain, improving oxygenation and reducing the frequency and intensity of migraine attacks.

This medication is particularly beneficial for individuals experiencing chronic migraines or vestibular disorders such as vertigo, as it helps to alleviate associated symptoms, including dizziness and nausea. Flunafeb 10 Tablet can also be used as part of a long-term preventive treatment plan under medical supervision.

Taken once daily, preferably at bedtime, Flunafeb 10 Tablet offers a convenient solution for individuals seeking relief from the debilitating effects of migraines and vertigo. With regular use, it not only reduces the occurrence of attacks but also enhances overall quality of life by improving functional capacity and reducing symptom-related disruptions.

Common side effects may include drowsiness, fatigue, weight gain, dry mouth, and nausea. Rarely, depression or movement disorders may occur.

Flunafeb 10 Tablet is indicated for the prevention of migraines and treatment of vertigo associated with vestibular disorders.

Use this medication strictly under medical supervision. Avoid activities requiring alertness, such as driving, if drowsiness occurs. Report any unusual side effects or worsening symptoms to your doctor promptly.

Store in a cool, dry place, away from direct sunlight and moisture. Keep out of reach of children.

Get in Touch

Regulatory Compliance & Professional Verification

This catalog is a digital representation of the Cafoli Lifecare portfolio and is intended for use by authorized pharmaceutical distributors and PCD franchise partners.

  • No Consumer Sale: We do not entertain retail inquiries or direct sales to patients.
  • Information Accuracy: While we strive for accuracy, product availability, packaging, and regulatory status may change based on CDSCO guidelines and state-specific drug laws.
  • Medical Advice: Patients are strictly advised not to self-medicate or use this information for treatment. Always consult a qualified medical practitioner.
  • Licensing: All business associations are subject to the submission of valid GST and Drug License (DL) documentation.

Frequently Asked Questions

What are the business opportunities for Flunarizine 10mg Tablet in the PCD pharma franchise market?

Flunarizine 10mg Tablet is used for migraine prevention, vertigo, and vestibular disorders, making it a strong neurology and CNS-care product for medical distributors, wholesalers, and pharma franchise partners in the PCD pharma pharma franchise market.

Why should medical distributors include Flunarizine 10mg Tablets in their product range?

Medical distributors and wholesalers can benefit from consistent demand in migraine prophylaxis, dizziness, vestibular disorders, and chronic headache management. It is commonly prescribed by neurologists and physicians for long-term prevention therapy.

Does Cafoli Lifecare offer PCD pharma franchise opportunities for this product?

Yes, Cafoli Lifecare offers PCD pharma pharma franchise opportunities for Flunarizine 10mg Tablet with monopoly rights, quality neurology formulations, competitive pricing, and reliable supply support for distributors and medical agencies.

What benefits do wholesalers get by partnering for this CNS product?

Wholesalers and medical agencies benefit from steady prescription demand in neurology clinics, migraine prevention therapy cycles, and long-term patient usage when partnering with Cafoli Lifecare.

How can I become a distributor or franchise partner for Flunarizine 10mg Tablet?

Medical distributors, stockists, wholesalers, and pharma professionals interested in this neurology formulation can contact Cafoli Lifecare to discuss PCD pharma franchise opportunities, pricing, and distribution support services.